menu
    • menu
    [{"orgOrder":0,"company":"Kanvas Biosciences","sponsor":"Federation Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Kanvas Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kanvas Biosciences \/ Kanvas Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Kanvas Biosciences \/ Kanvas Biosciences"},{"orgOrder":0,"company":"Kanvas Biosciences","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Funding","leadProduct":"KAN-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Kanvas Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Kanvas Biosciences \/ DCVC Bio","highestDevelopmentStatusID":"4","companyTruncated":"Kanvas Biosciences \/ DCVC Bio"}]

    Find Clinical Drug Pipeline Developments & Deals by Kanvas Biosciences

    Menu

    Kanvas Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kanvas Biosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Kanvas Biosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KAN-001

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : DCVC Bio

                            Deal Size : $29.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Kanvas Biosciences Raises $12.5M in Additional Funding

                            Details : The funding will be used to advance the development of the company's lead product KAN-001, which is being evaluated in the early-stage clinical trial studies for the treatment of neoplasms.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            February 07, 2024

                            Lead Product(s) : KAN-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : DCVC Bio

                            Deal Size : $29.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kanvas Biosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Kanvas Biosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Recipient : Federation Bio

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Kanvas Biosciences Acquires Federation Bio Assets to Scale the Discovery, Development and Manufacturing of Mic...

                            Details : As part of the asset acquisition, Kanvas Biosciences will advance two core initiatives that improve the treatment of prevalent diseases: Immuno-oncology program and Inflammatory Bowel Disease program.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 10, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Recipient : Federation Bio

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth